Aequus Pharmaceuticals Inc. has released its third quarter 2024 financial highlights, showing notable stock price volatility and a recent increase in value, despite a market capitalization of $661,890 USD.

Aequus Pharmaceuticals Inc. has had its shares halted from trading due to regulatory scrutiny, amid ongoing financial struggles and a failure to meet exchange requirements.